Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Primary Purpose
Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Dapagliflozin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring dapagliflozin, diabetes, cardiovascular disease
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes mellitus.
- Cardiovascular disease
- Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment
Exclusion Criteria:
- Patients with type 1 diabetes or diabetes insipidus
- Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
- Any clinically significant illness, which would compromise the patient's safety and their participation in the study
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
1
2
Arm Description
dapagliflozin 10 mg tablet
matching placebo tablet
Outcomes
Primary Outcome Measures
Adjusted Mean Change in HbA1c Levels
To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.
Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.
Secondary Outcome Measures
Adjusted Mean Percent Change in Body Weight
To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²
To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.
Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF)
To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.
Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF)
To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg
To compare the mean change in seated systolic blood pressure (SBP) in participants with baseline seated SBP ≥130 mmHg achieved with dapagliflozin versus placebo from baseline to week 8.
Full Information
NCT ID
NCT01042977
First Posted
January 5, 2010
Last Updated
December 18, 2013
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
1. Study Identification
Unique Protocol Identification Number
NCT01042977
Brief Title
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Official Title
A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care
Study Type
Interventional
2. Study Status
Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
4. Oversight
5. Study Description
Brief Summary
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Keywords
dapagliflozin, diabetes, cardiovascular disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
964 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
dapagliflozin 10 mg tablet
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
matching placebo tablet
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Intervention Description
10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Primary Outcome Measure Information:
Title
Adjusted Mean Change in HbA1c Levels
Description
To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.
Time Frame
Baseline to Week 24
Title
Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Description
To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.
Time Frame
Baseline to Week 24
Secondary Outcome Measure Information:
Title
Adjusted Mean Percent Change in Body Weight
Description
To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Time Frame
Baseline to Week 24
Title
Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²
Description
To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.
Time Frame
Baseline to Week 24
Title
Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF)
Description
To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.
Time Frame
Baseline to Week 8
Title
Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF)
Description
To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Time Frame
Baseline to Week 24
Title
Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg
Description
To compare the mean change in seated systolic blood pressure (SBP) in participants with baseline seated SBP ≥130 mmHg achieved with dapagliflozin versus placebo from baseline to week 8.
Time Frame
Baseline to Week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes mellitus.
Cardiovascular disease
Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment
Exclusion Criteria:
Patients with type 1 diabetes or diabetes insipidus
Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
Any clinically significant illness, which would compromise the patient's safety and their participation in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Lawrence A Leiter, MD
Organizational Affiliation
Division of Endocrinology & Metabolism, St Michael's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Scottsdale
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Anaheim
State/Province
California
Country
United States
Facility Name
Research Site
City
Bell Gardens
State/Province
California
Country
United States
Facility Name
Research Site
City
Chino
State/Province
California
Country
United States
Facility Name
Research Site
City
Chula Vista
State/Province
California
Country
United States
Facility Name
Research Site
City
Huntington Beach
State/Province
California
Country
United States
Facility Name
Research Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
Research Site
City
Mission Hills
State/Province
California
Country
United States
Facility Name
Research Site
City
Redondo Beach
State/Province
California
Country
United States
Facility Name
Research Site
City
Riverside
State/Province
California
Country
United States
Facility Name
Research Site
City
Sacramento
State/Province
California
Country
United States
Facility Name
Research Site
City
San Diego
State/Province
California
Country
United States
Facility Name
Research Site
City
Torrance
State/Province
California
Country
United States
Facility Name
Research Site
City
Aventura
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Boca Raton
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Bradenton
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Brooksville
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Dania
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Delray Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
New Smyrna Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Springfield
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Avon
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Franklin
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Greenfield
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Muncie
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Waterloo
State/Province
Iowa
Country
United States
Facility Name
Research Site
City
Topeka
State/Province
Kansas
Country
United States
Facility Name
Research Site
City
Paducah
State/Province
Kentucky
Country
United States
Facility Name
Research Site
City
Alexandria
State/Province
Louisiana
Country
United States
Facility Name
Research Site
City
Rockville
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Kalamazoo
State/Province
Michigan
Country
United States
Facility Name
Research Site
City
Livonia
State/Province
Michigan
Country
United States
Facility Name
Research Site
City
Billings
State/Province
Montana
Country
United States
Facility Name
Research Site
City
Berlin
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Brick
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Asheboro
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Fargo
State/Province
North Dakota
Country
United States
Facility Name
Research Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
Research Site
City
Altoona
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Erie
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Holland
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Lancaster
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Media
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Corpus Christi
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Irving
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Richardson
State/Province
Texas
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Sugarland
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Alexandria
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Manassas
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Buenos Aires
State/Province
Caba
Country
Argentina
Facility Name
Research Site
City
Rosario
State/Province
Santa Fe
Country
Argentina
Facility Name
Research Site
City
Cordoba
Country
Argentina
Facility Name
Research Site
City
Salta
Country
Argentina
Facility Name
Research Site
City
Santa Fe
Country
Argentina
Facility Name
Research Site
City
Blacktown
State/Province
New South Wales
Country
Australia
Facility Name
Research Site
City
Broadmeadow
State/Province
New South Wales
Country
Australia
Facility Name
Research Site
City
Hornsby
State/Province
New South Wales
Country
Australia
Facility Name
Research Site
City
Wollongong
State/Province
New South Wales
Country
Australia
Facility Name
Research Site
City
Carina Heights
State/Province
Queensland
Country
Australia
Facility Name
Research Site
City
Kippa-ring
State/Province
Queensland
Country
Australia
Facility Name
Research Site
City
Adelaide
State/Province
South Australia
Country
Australia
Facility Name
Research Site
City
Bedford Park
State/Province
South Australia
Country
Australia
Facility Name
Research Site
City
Keswick
State/Province
South Australia
Country
Australia
Facility Name
Research Site
City
Box Hill
State/Province
Victoria
Country
Australia
Facility Name
Research Site
City
Heidelberg
State/Province
Victoria
Country
Australia
Facility Name
Research Site
City
Herston
Country
Australia
Facility Name
Research Site
City
Wien
Country
Austria
Facility Name
Research Site
City
Blagoevgrad
Country
Bulgaria
Facility Name
Research Site
City
Pernik
Country
Bulgaria
Facility Name
Research Site
City
Pleven
Country
Bulgaria
Facility Name
Research Site
City
Russe
Country
Bulgaria
Facility Name
Research Site
City
Sevlievo
Country
Bulgaria
Facility Name
Research Site
City
Sofia
Country
Bulgaria
Facility Name
Research Site
City
Stara Zagora
Country
Bulgaria
Facility Name
Research Site
City
Varna
Country
Bulgaria
Facility Name
Research Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
Research Site
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
Research Site
City
Moncton
State/Province
New Brunswick
Country
Canada
Facility Name
Research Site
City
Bay Roberts
State/Province
Newfoundland and Labrador
Country
Canada
Facility Name
Research Site
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
Research Site
City
Etobicoke
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Scarborough
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Thornhill
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Mirabel
State/Province
Quebec
Country
Canada
Facility Name
Research Site
City
Quebec
Country
Canada
Facility Name
Research Site
City
Santiago
State/Province
Region Metropolitana
Country
Chile
Facility Name
Research Site
City
Damme
Country
Germany
Facility Name
Research Site
City
Dortmund
Country
Germany
Facility Name
Research Site
City
Homburg
Country
Germany
Facility Name
Research Site
City
Munster
Country
Germany
Facility Name
Research Site
City
Wangen
Country
Germany
Facility Name
Research Site
City
Ajka
Country
Hungary
Facility Name
Research Site
City
Balatonfured
Country
Hungary
Facility Name
Research Site
City
Budapest
Country
Hungary
Facility Name
Research Site
City
Esztergom
Country
Hungary
Facility Name
Research Site
City
Gyor
Country
Hungary
Facility Name
Research Site
City
Komarom
Country
Hungary
Facility Name
Research Site
City
Mosonmagyarovar
Country
Hungary
Facility Name
Research Site
City
TAT
Country
Hungary
Facility Name
Research Site
City
Veszprem
Country
Hungary
Facility Name
Research Site
City
Bialystok
Country
Poland
Facility Name
Research Site
City
Chrzanow
Country
Poland
Facility Name
Research Site
City
Gdansk
Country
Poland
Facility Name
Research Site
City
Grodzisk Mazowiecki
Country
Poland
Facility Name
Research Site
City
Ilawa
Country
Poland
Facility Name
Research Site
City
Kielce
Country
Poland
Facility Name
Research Site
City
Krakow
Country
Poland
Facility Name
Research Site
City
Leczna
Country
Poland
Facility Name
Research Site
City
Leczyca
Country
Poland
Facility Name
Research Site
City
Lodz
Country
Poland
Facility Name
Research Site
City
Lublin
Country
Poland
Facility Name
Research Site
City
Mragowo
Country
Poland
Facility Name
Research Site
City
Nowy Sacz
Country
Poland
Facility Name
Research Site
City
Plock
Country
Poland
Facility Name
Research Site
City
Poznan
Country
Poland
Facility Name
Research Site
City
Ruda Slaska
Country
Poland
Facility Name
Research Site
City
Skierniewice
Country
Poland
Facility Name
Research Site
City
Sopot
Country
Poland
Facility Name
Research Site
City
Tarnow
Country
Poland
Facility Name
Research Site
City
Torun
Country
Poland
Facility Name
Research Site
City
Warszawa
Country
Poland
Facility Name
Research Site
City
Wroclaw
Country
Poland
Facility Name
Research Site
City
Zabrze
Country
Poland
Facility Name
Research Site
City
Zgierz
Country
Poland
Facility Name
Research Site
City
Zielona Gora
Country
Poland
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
We'll reach out to this number within 24 hrs